Evercore ISI maintains Outperform on Zimmer Biomet, cuts target to $110
Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating on Zimmer Biomet Holdings (NYSE: ZBH) but lowered the price target to $110 from $120.

*this image is generated using AI for illustrative purposes only.
Evercore ISI Group analyst Vijay Kumar has maintained an Outperform rating on Zimmer Biomet Holdings while adjusting the valuation outlook. The firm lowered the price target for the stock to $110, down from the previous target of $120.
The revision reflects a reassessment of the company's share price potential despite the continued positive performance expectation. Zimmer Biomet Holdings trades on the NYSE under the ticker symbol ZBH.
What specific factors led Evercore ISI to reassess Zimmer Biomet's share price potential despite maintaining an Outperform rating?
How might the lowered price target impact investor sentiment towards Zimmer Biomet in the short term?
What upcoming catalysts or events could drive Zimmer Biomet's stock closer to the new $110 price target?






















